8-K: BEN Secures AI Deal with Global Ad Agency for Pharma Client

Brand Engagement Network Inc. announced a new Vendor Services Project Agreement to develop a custom AI engagement solution for a top-10 global pharmaceutical client, expecting $250,000 in Q4 2025 revenue and recurring fees in Q1 2026.

Summary

• Brand Engagement Network, Inc. (BEN) entered into a Vendor Services Project Agreement on December 19, 2025, with a leading global advertising and communications agency.
• The agreement is for the development of a custom AI engagement communication solution supporting an established prescription pharmaceutical product for a top-10 global pharmaceutical client.
• BEN expects to recognize $250,000 in revenue during the fourth quarter of 2025 for development services under two Statements of Work.
• Monthly recurring license fees are anticipated to begin in the first quarter of 2026, contingent on final implementation and deployment.
• The identities of the agency and pharmaceutical company remain confidential pending the formal release of the AI solution.
• This agreement, along with existing Latin American partnerships and the Skye Salud platform, is expected to positively contribute to the company's Q4 2025 results and demonstrates increasing adoption of BEN's AI technology in the healthcare sector.

Sentiment

Score: 8

Explanation: The filing announces a significant new agreement with a major client and agency, bringing immediate revenue and the promise of recurring revenue. It validates the company's technology in a key vertical and is explicitly stated to contribute positively to Q4 results. The only reason it's not higher is the lack of specific financial projections beyond the initial $250k and the general nature of the recurring fees.

Positives

• Secured a new Vendor Services Project Agreement with a leading global advertising agency for a top-10 global pharmaceutical client.
• Expected to recognize $250,000 in revenue during Q4 2025 from development services.
• Anticipates monthly recurring license fees starting in Q1 2026, indicating potential for ongoing revenue streams.
• Highlights increasing adoption of BEN's secure AI technology within the healthcare vertical in both the U.S. and Mexico.
• The agreement is expected to contribute positively to the company's Q4 2025 financial results.
• Reinforces BEN's progression in the healthcare sector, delivering trusted, secured, and efficient AI solutions.

Risks

• Limited operating history.
• Ability to achieve profitability in the future.
• Ability to demonstrate the value of the solution to customers.
• Ability to attract new customers and convince them of the value of the solution.
• Ability to retain and expand relationships with existing customers.
• Dependence on senior management team and other key employees.
• Downturns in the economy and reductions in advertising and marketing spend.
• Presence in the emerging and evolving market for generative AI products and services.
• Ability to manage growth effectively.
• Impact of geopolitical and macroeconomic instability.
• Intense competition in the industry.
• Reliance on third-party platforms.
• Changes in applicable laws or regulations and complexities with newly emerging technologies.
• Cyber privacy and security concerns.
• Ability to maintain, protect, and enhance intellectual property rights.
• Ability to successfully identify, execute, and integrate future acquisitions.

Future Outlook

The company anticipates recognizing $250,000 in revenue during Q4 2025 from the new agreement and expects monthly recurring license fees to begin in Q1 2026. This, combined with existing Latin American initiatives, is projected to positively contribute to Q4 2025 results and signifies growing adoption of BEN's AI technology in the healthcare sector.

Management Comments

• "This agreement reflects BEN's progression in healthcare, in which our technology delivers trusted, secured, and efficient AI for pharma manufacturers, healthcare providers, and patients."
• "We are committed to creating experiences for consumers where their needs are met with accuracy, reliability, and integrity."

Industry Context

This agreement positions Brand Engagement Network within the rapidly expanding market for generative AI solutions, particularly in specialized verticals like healthcare. The partnership with a major advertising agency and a top pharmaceutical client underscores the growing demand for secure, compliant, and effective AI communication tools to enhance patient engagement and brand interaction in a highly regulated industry. It also highlights the trend of AI being integrated into marketing and customer experience strategies.

Stakeholder Impact

• Shareholders: Positive impact due to new revenue, potential for recurring revenue, validation of technology, and positive contribution to Q4 2025 results, potentially increasing share price.
• Customers (Agency/Pharma Client): Will benefit from a custom AI engagement communication solution to support their pharmaceutical product.
• Employees: Continued work on developing and deploying advanced AI solutions.

Next Steps

• Formal release of the AI solution (identities of agency and pharma client to be disclosed then).
• Final implementation and deployment of the AI solution to enable monthly recurring license fees.

Key Dates

Recommendation

The announcement of a new material agreement with a leading global advertising agency and a top-10 global pharmaceutical client is a significant positive development. The immediate recognition of $250,000 in Q4 2025 revenue, coupled with the anticipation of monthly recurring license fees starting in Q1 2026, indicates strong business momentum and a validated product in the high-growth healthcare AI sector. This deal expands the company's footprint and provides a clear path to future revenue streams, making it an attractive investment opportunity for growth-oriented investors.

Keywords

Generative AI, AI engagement solution, Healthcare AI, Pharmaceutical industry, Advertising agency, Recurring revenue, Brand Engagement Network, BNAI, SEC filing, Vendor Services Agreement